NASDAQ:VRMLVermillion Stock Price, Forecast & News

$0.93

+0.04 (+4.48 %)

(As of 04/10/2020 02:02 AM ET)

Add

Compare

Today's Range

$0.90

Now: $0.93▼

$0.94

50-Day Range

$0.64

MA: $0.83▼

$0.95

52-Week Range

$0.35

Now: $0.93▼

$1.57

Volume58,705 shs

Average Volume178,763 shs

Market Capitalization$90.70 million

P/E RatioN/A

Dividend YieldN/A

Beta2.52

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Vermillion.

2.5 Community Rank

Outperform Votes
Vermillion has received 202 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Vermillion has received 204 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Vermillion has received 50.25% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote “Outperform” if you believe VRML will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRML will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Vermillion does not currently pay a dividend.
Dividend Growth
Vermillion does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vermillion insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.40% of the stock of Vermillion is held by insiders.
Percentage Held by Institutions
Only 18.11% of the stock of Vermillion is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Vermillion is -5.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vermillion is -5.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vermillion has a P/B Ratio of 10.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.50 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VRML

Previous Symbol

CUSIPN/A

CIK926617

Webhttp://www.vermillion.com/

Phone512-519-0400

Debt

Debt-to-Equity Ratio0.10

Current Ratio4.54

Quick Ratio4.53

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.54 million

Price / Sales19.98

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.09 per share

Price / Book10.36

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-15,240,000.00

Net Margins-335.77%

Return on Equity-158.55%

Return on Assets-106.46%

Miscellaneous

Employees43

Outstanding Shares97,240,000

Market Cap$90.70 million

Next Earnings Date5/12/2020 (Estimated)

OptionableOptionable

Receive VRML News and Ratings via Email

Sign-up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter.

Vermillion (NASDAQ:VRML) Frequently Asked Questions

How has Vermillion's stock been impacted by COVID-19 (Coronavirus)?

Vermillion's stock was trading at $0.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VRML stock has increased by 11.0% and is now trading at $0.9327. View which stocks have been most impacted by Coronavirus.

When is Vermillion's next earnings date?

Vermillion is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Vermillion.

How were Vermillion's earnings last quarter?

Vermillion, Inc. (NASDAQ:VRML) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.06) earnings per share (EPS) for the quarter. The company had revenue of $1.14 million for the quarter. Vermillion had a negative return on equity of 158.55% and a negative net margin of 335.77%. View Vermillion's earnings history.

Has Vermillion been receiving favorable news coverage?

Media headlines about VRML stock have trended very negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vermillion earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutVermillion.

Who are some of Vermillion's key competitors?

Some companies that are related to Vermillion include Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), ImmuCell (ICCC), Trinity Biotech (TRIB), GeneNews (GNWSF), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), BG Medicine (BGMD), Fluoropharma Medical (FPMI) and Response Genetics (RGDXQ).

What other stocks do shareholders of Vermillion own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vermillion investors own include CombiMatrix (CBMX), TrovaGene (TROV), Accelerate Diagnostics (AXDX), Himax Technologies (HIMX), Opko Health (OPK), NovaBay Pharmaceuticals (NBY), Charter Communications (CHTR), Fluidigm (FLDM), Idera Pharmaceuticals (IDRA) and Genworth Financial (GNW).

Who are Vermillion's key executives?

Vermillion's management team includes the following people:

Ms. Valerie Barber Palmieri, CEO, Pres & Director (Age 58)
Mr. Robert Harry Beechey CPA, Chief Financial Officer (Age 56)
Mr. Chris Goulart, Sr. VP of Commercial Operations

What is Vermillion's stock symbol?

Vermillion trades on the NASDAQ under the ticker symbol "VRML."

How do I buy shares of Vermillion?

Shares of VRML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vermillion's stock price today?

One share of VRML stock can currently be purchased for approximately $0.93.

How big of a company is Vermillion?

Vermillion has a market capitalization of $90.70 million and generates $4.54 million in revenue each year. Vermillion employs 43 workers across the globe. View additional information about Vermillion.

What is Vermillion's official website?

The official website for Vermillion is http://www.vermillion.com/.

How can I contact Vermillion?

Vermillion's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at 512-519-0400 or via email at [email protected]

This page was last updated on 4/10/2020 by MarketBeat.com Staff